Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Norfolk Southern Corporation — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Norfolk Southern Corporation trades at $326.37 (market cap $72.13B). The key difference: Norfolk Southern Corporation is far larger — about 25.2× Dyne Therapeutics Inc. Common Stock's market cap, and Norfolk Southern Corporation pays a 1.68% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Norfolk Southern Corporation for 34 Days on average.
| DYN | NSC | |
|---|---|---|
Market Cap | $2.86B | $72.13B |
Volume | 3,341,579 | 650,750 |
Sector | Health | Industrials |
52-Week High | $26.78 | $352.98 |
52-Week Low | $14.60 | $278.19 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $2.18B | $87.68B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Norfolk Southern (NSC) trades at $321.14, up 0.56% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (21.02% net margin). Recent news highlights momentum for the Union Pacific merger, while institutional buying and a $361.86 consensus price target suggest upside potential.
Outlook remains positive with merger progress and dividend stability, but risks include fuel cost pressures and regulatory hurdles. The current valuation (P/E 27.4) demands execution on freight share gains and merger benefits to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
